← Back to Screener
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
Price$6.44
Favorite Metrics
Price vs S&P 500 (26W)-24.45%
Price vs S&P 500 (4W)24.74%
Market Capitalization$207.15M
All Metrics
Book Value / Share (Quarterly)$3.42
P/TBV (Annual)3.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.40
Price vs S&P 500 (YTD)5.15%
EPS (TTM)$-1.79
10-Day Avg Trading Volume0.39M
EPS Excl Extra (TTM)$-1.79
EPS (Annual)$-1.58
ROI (Annual)-45.82%
Cash / Share (Quarterly)$3.48
ROA (Last FY)-43.82%
EBITD / Share (TTM)$-1.99
ROE (5Y Avg)-51.85%
Cash Flow / Share (Annual)$-1.40
P/B Ratio1.86x
P/B Ratio (Quarterly)1.65x
Net Income / Employee (Annual)$-3
ROA (TTM)-40.31%
EPS Incl Extra (Annual)$-1.58
Current Ratio (Annual)22.82x
Quick Ratio (Quarterly)22.27x
3-Month Avg Trading Volume0.55M
52-Week Price Return220.30%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.27
P/S Ratio (Annual)103.58x
Asset Turnover (Annual)0.02x
52-Week High$11.41
EPS Excl Extra (Annual)$-1.58
26-Week Price Return-15.70%
Quick Ratio (Annual)22.27x
13-Week Price Return1.57%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)22.82x
Enterprise Value$172.133
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1393.80%
Cash / Share (Annual)$3.48
3-Month Return Std Dev78.93%
Net Income / Employee (TTM)$-4
ROE (Last FY)-45.82%
EPS Basic Excl Extra (Annual)$-1.58
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.79
ROI (TTM)-42.39%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.28
Price vs S&P 500 (52W)185.20%
Year-to-Date Return9.29%
5-Day Price Return19.37%
EPS Normalized (Annual)$-1.58
ROA (5Y Avg)-46.96%
Net Profit Margin (Annual)-1393.80%
Month-to-Date Return23.83%
EBITD / Share (Annual)$-1.76
Operating Margin (Annual)-1537.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-51.85%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.79
P/TBV (Quarterly)0.90x
P/B Ratio (Annual)1.65x
Book Value / Share (Annual)$3.42
Price vs S&P 500 (13W)-1.30%
Beta3.22x
Revenue / Share (TTM)$0.00
ROE (TTM)-42.39%
52-Week Low$2.02
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.22
4.22
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SGMTSagimet Biosciences Inc. Series A Common Stock | — | — | — | — | $6.44 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing selective fatty acid synthase (FASN) inhibitors to treat metabolic diseases driven by dysfunctional lipid metabolism. The company's lead candidate, denifanstat, is an oral, once-daily FASN inhibitor in development for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated liver disease. Sagimet is focused on advancing its proprietary FASN inhibitor platform across multiple indications where lipid dysregulation plays a pathogenic role.